Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HCC × Radiosurgery × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Brain Neoplasms 104 Carcinoma, Non-Small-Cell Lung 95 Prostatic Neoplasms 94 Neoplasm Metastasis 74 Lung Neoplasms 57 Pancreatic Neoplasms 56 Carcinoma, Hepatocellular 56 Breast Neoplasms 43 Melanoma 36 Carcinoma, Renal Cell 29 Neoplasms 28 Glioblastoma 18 Colorectal Neoplasms 18 Squamous Cell Carcinoma of Head and Neck 16 Liver Neoplasms 15 Small Cell Lung Carcinoma 12 Head and Neck Neoplasms 11 Sarcoma 10 Kidney Neoplasms 10 Glioma 10 Recurrence 8 Urinary Bladder Neoplasms 6 Radiation Injuries 6 Neuroma, Acoustic 6 Adenocarcinoma 6 Uveal Melanoma 5 Uterine Cervical Neoplasms 5 Prostate Cancer Metastatic 5 Ovarian Neoplasms 5 Meningioma 5

Interventions

nimotuzumab 1 atezolizumab 1 Stents 1 Sorafenib 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡